Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of “Moderate Buy” by Analysts

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has been assigned an average recommendation of “Moderate Buy” from the twenty-one research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and nineteen have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $206.2222.

AXSM has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Axsome Therapeutics in a research note on Wednesday, January 14th. Oppenheimer restated an “outperform” rating and issued a $220.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, December 31st. Guggenheim reiterated a “buy” rating and set a $205.00 price objective on shares of Axsome Therapeutics in a research note on Friday, January 2nd. Royal Bank Of Canada boosted their target price on Axsome Therapeutics from $212.00 to $219.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 21st.

Insiders Place Their Bets

In related news, CEO Herriot Tabuteau sold 91,705 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $132.34, for a total value of $12,136,239.70. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at $956,685.86. The trade was a 92.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark E. Saad sold 37,577 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the transaction, the director directly owned 10,002 shares in the company, valued at $1,652,130.36. This trade represents a 78.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 440,403 shares of company stock valued at $67,191,178. Insiders own 22.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AXSM. Versant Capital Management Inc boosted its position in shares of Axsome Therapeutics by 20,300.0% during the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after buying an additional 203 shares during the last quarter. First Horizon Corp purchased a new position in Axsome Therapeutics in the 3rd quarter worth about $34,000. Optiver Holding B.V. lifted its stake in Axsome Therapeutics by 82.3% during the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after acquiring an additional 130 shares during the period. Essex Investment Management Co. LLC purchased a new stake in shares of Axsome Therapeutics during the 3rd quarter valued at about $38,000. Finally, Advisory Services Network LLC purchased a new stake in shares of Axsome Therapeutics during the 3rd quarter valued at about $40,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

AXSM opened at $184.25 on Friday. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. The company has a market cap of $9.29 billion, a price-to-earnings ratio of -39.45, a price-to-earnings-growth ratio of 9.77 and a beta of 0.44. The stock has a fifty day simple moving average of $163.29 and a two-hundred day simple moving average of $135.88. Axsome Therapeutics has a 12-month low of $86.99 and a 12-month high of $191.50.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The business had revenue of $170.99 million during the quarter, compared to analysts’ expectations of $162.96 million. The firm’s revenue was up 63.2% on a year-over-year basis. Research analysts predict that Axsome Therapeutics will post -2.79 earnings per share for the current fiscal year.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.